CXCR4 overexpression in solid tumors has been strongly associated with poor prognosis and adverse clinical outcome. However, CXCR4 signaling inhibitor drug Plerixafor has shown limited clinical success in cancer treatment. Therefore, CXCR4 signaling may not be the exclusive contributor to its pro-tumorigenic functions. In our continuous effort to understand the chemokine receptor signaling inhibition as cancer therapy, here we unexpectedly discovered that instead of its signaling, intracellular CXCR4 protein augments therapy resistance and pro-tumorigenic functions. Unbiased proteome profiler apoptosis array followed by immunoblot, FACS, real-time PCR and ChIP analyses demonstrate that CXCR4 promotes DR5 downregulation via modulating differential recruitment of transcription factors p53 and YY1 to its promoter. Surprisingly, inhibiting CXCR4 mediated signals failed to block the above phenotype. Irrespective of CXCR4 surface expression, its loss compromised colon tumor growth in vivo. Finally, TCGA data mining and human patient sample data analysis showed CXCR4 and DR5 are inversely regulated in human cancers. Together, we showed evidence for the first time that targeting CXCR4 intracellular protein may be critical to dampen the pro-tumorigenic functions of CXCR4. explain the pro-tumorigenic functions of these axes. In our relentless effort to understand the chemokine receptor signaling inhibition in cancer therapy [15, [19] [20] [21] [22] , here we surprisingly discovered that neither CXCR7 nor CXCR4-CXCL12 signaling axis is responsible for therapy resistance and tumorigenic potential, rather CXCR4 protein in the cancer cells plays a very critical role in positively modulating pro-tumorigenic functions such as therapy resistance across multiple solid tumors. Our intricate in vitro and in vivo experiments in multiple cancer settings for CXCR4 gain and loss of function studies demonstrate that CXCR4 protein but not its CXCL12 mediated signals modulate chemotherapy resistance and tumorigenic potential via inversely regulating the expression of DR5. CXCR4-DR5 inverse regulation was also validated in diverse human cell lines and human cancer patient samples, suggesting its possible therapeutic implications.
Introduction
Cancer is the 2nd leading cause of death globally and was responsible for an estimated 9.6 million deaths in 2018 [1] . Drug resistance or inadequate chemotherapy response in patients is one of the pivotal reasons for cancer-associated colossal mortality and morbidity. Therefore, there is a dire need to understand the molecular mechanisms lying behind cancer therapy resistance. Cancer cells become therapy resistant by smartly evading the execution of apoptosis posed by chemotherapeutic drugs [2, 3] . The evasion of apoptosis by cancer cells largely relies on tilting the balance towards the increased expression of anti-apoptotic genes against pro-apoptotic genes [4, 5] . Death Receptors (DR) are critical pro-apoptotic factors present in healthy cells, immensely regulate cell death, and extensive literature suggests that paucity of death receptors in cancer cells promotes therapy resistance in diverse solid tumors [6] [7] [8] . So, the restoration of the functional death receptors is an attractive strategy to sensitize cancer cells against chemotherapy.
Over the last decade or so, chemokine receptor CXCR4 has been extensively reported to be overexpressed in most human solid tumors, and its association is strongly correlated with poor prognosis and adverse clinical outcomes [9, 10] . CXCR4 ligand (CXCL12) mediated signals are well established to explain its enormous role in modulating organ-specific metastasis of solid tumors [11] [12] [13] . Still, its effect on other pro-tumorigenic functions like therapy resistance and tumor-initiating capabilities are poorly understood. Moreover, multiple inhibitors of the CXCL12-CXCR4 axis, such as AMD3100 or plerixafor, and Nox-A12 have shown limited clinical success in cancer treatment [14] . These observations pose a serious concern regarding the contribution of the CXCL12-CXCR4 signaling axis in the pro-tumorigenic role of CXCR4. Earlier, we and others have extensively reviewed the dogma and opined that CXCR7, another CXCL12 high-affinity binding receptor could be the reason for the limited success of CXCR4 blockade in clinics [14] [15] [16] [17] [18] .
Unfortunately, recent preclinical data for blocking both the chemokine receptors also failed to BD Biosciences. Nonconjugated CXCR4, CXCR7 monoclonal antibodies, chemokine CXCL12, and CXCR4 antagonist peptide AMD3100 were procured from R&D systems. All chemicals and antibodies were obtained from Sigma unless specified otherwise.
Cell Culture
Human breast cancer cell lines MCF7, MDA-MB-468, colon cancer cell lines DLD1, HCT 116, HT 29, COLO 205, SW 620, lung cancer cell lines A549, NCI-H-358 and prostate cancer cell line PC3 were obtained from American Type Culture Collection (ATCC), USA. Mycoplasma free early passage cells were resuscitated from liquid nitrogen vapor stocks and inspected microscopically for stable phenotype before use. MCF7, MDA-MB-468, DLD1, HT 29, COLO 2O5, A549, NCI-H-358, and PC3 cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum (Gibco/Invitrogen), supplemented with anti-anti (Invitrogen). SW 620 cells were cultured in DMEM medium containing 10% fetal bovine serum (Gibco/Invitrogen), supplemented with anti-anti (Invitrogen). The HCT116 cell line was cultured in McCoy's medium containing 10% fetal bovine serum (Gibco/Invitrogen), supplemented with anti-anti (Invitrogen).
Cytotoxicity assay (SRB assay)
In vitro cytotoxic activities of Doxorubicin, Paclitaxel, 5-Fluorouracil, Cisplatin, TRAIL, and AMD3100 were assessed by using standard SRB assay as described before [23, 24] . The absorbance of the treated and untreated cells was measured on a multi-well scanning spectrophotometer (Epoch Microplate Reader, Biotek, USA) at a wavelength of 510 nm. Percent inhibition in cell growth was calculated by using the formula [100-(Absorbance of compound treated cells/ Absorbance of untreated cells)] X 100.
Flow cytometry
Cell surface expression of CXCR4, CXCR7 and DR5 in different cell lines was analyzed by Flow cytometry. In brief, cells were allowed to grow up to 70-80% confluence and then harvested with TrypLE (Invitrogen) for single-cell suspension in FACS buffer (PBS with 0.1% BSA). Cells were stained with fluorochrome-conjugated antibodies in FACS buffer for 30-45 min at room temperature in the dark. After washing and centrifugation, cell pellets were resuspended in FACS buffer and analyzed by FACS Calibur (BD). Acquired data were analyzed using FlowJo software (Treestar).
Cell sorting was carried out by FACS Aria (BD).
DiL DiO Staining
For staining the lipophilic dye DiL (1,1'-Dioctadecyl-3,3,3',3' Tetramethylindocarbocyanine Perchlorate) and DiO (3,3'-Dioctadecyloxacarbocyanine Perchlorate), cells were stained with 10μM of DiL (Red), and DiO (Green) dyes solution respectively for 45 min at 37°C. After that, cells were spun down, rinsed, and resuspended in fresh medium and seeded in 12-well plates. The next day, cells were treated with the chemotherapeutic agents at the desired concentration and visualized under the microscope at different timings or harvested for the analysis in FACS Calibur. For FACS analysis, DiL and DiO stained cells were harvested, washed, centrifuged, and resuspended in FACS buffer for analysis. Cells were analyzed under FL3 and FL1 channels in FACS Calibur.
Western blotting
Cells were lysed in RIPA buffer containing phosphatase and protease inhibitor cocktail. Protein concentration was estimated by using the BCA kit. Equal amounts of protein were resolved by SDS-PAGE and transferred to a PVDF membrane [19, 25] . Membranes were blocked with 5% nonfat dry milk or 5% BSA followed by incubation with appropriate dilutions (1:1000) of primary antibodies overnight at 4°C and subsequently incubated with a 1:5000 dilution of horseradish peroxidaseconjugated secondary antibodies for 1 hour at room temperature. Immunoreactivity was detected by enhanced chemiluminescence solution (ImmobilonTM western, Millipore, USA) and scanned by the gel documentation system (Bio-Rad chemidoc XRS plus). To detect CXCR4 in western blot, we followed separate sample preparation as per manufacturer's instruction.
Apoptosis antibody array analysis
Apoptosis array was performed by using Proteome Profiler Human Apoptosis Array Kit (ARY009) from R&D Systems following manufacturer's instructions. Detailed assay procedure was followed as described before [22] . The images were captured by the gel documentation system (Bio-Rad chemidoc XRS plus), while ImageJ software (NIH) was used for analysis. Plotly software was used for heatmap generation (Montreal, Canada).
Real-time PCR
Total RNA was isolated from the cultured cells and tissues using the standard procedure of the RNeasy Mini Kit (Qiagen, cat no.74104). The concentration and purity of the RNA samples was determined using nanodrop. Total RNA (5 μg) of each sample was reverse-transcribed (RT) with random hexamer according to the manufacturer's protocol (Verso cDNA synthesis kit). The final cDNA was diluted with nuclease-free water (1:3), 1μl of this having a concentration of 25ng/μl was used for each reaction in real-time PCR. Real-time PCR was carried out using an ABI StepOnePlus
Real-Time PCR System (Applied Biosystems). TaqMan gene expression assay from Thermo Fisher
Scientific was used for CXCR4 (Assay ID: Hs00607978_s1), CXCR7 (Assay ID: Hs00664172_s1), and DR5 (Assay ID: Hs00366278_m1) gene amplification. Reactions for each sample were performed in triplicate. GAPDH or 18s amplification was used as the housekeeping gene. A gene expression score was calculated by taking two raised to the difference in Ct between the housekeeping gene and the gene of interest (2 ΔCt). For amplifying YY1, p53, Sp1, we performed SYBR Green based RT-PCR following manufacturer's instructions.
Generation of stable cell lines
CXCR4 (cat#CXCR400000), CXCR7 (cat#CXCR700000), or empty vector pcDNA 3.1 (cat# V790-20) were procured from cDNA Resource Center. For stable overexpression of chemokine receptors CXCR4 and CXCR7, MCF7 cells were plated and transfected with either overexpression plasmids or empty vector individually by using Lipofectamine LTX as transfection reagent (Invitrogen). After 48 hours of transfection, cells were cultured in the presence of suboptimal dose (600µg/ml) of Geneticin (G418) for 15 days with refreshing the medium at every 3rd day for the selection of vector containing cells. The expression level for CXCR4 and CXCR7 was evaluated through flow cytometry. 3rd generation lentiviral vector pUltra-Chili-Luc (addgene no. 48688) with the bi-cistronic expression of tdTomato and Luciferase was used to make HT29 cells fluorescent. Lentiviral particles were generated in HEK-293T cells. Transduction was carried out in the presence of Polybrene (8μg/ml). A population of transduced cells (HT29-Chili-Luc) was identified by chili red expression and sorted by flow cytometry.
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Chromatin Immunoprecipitation (ChIP)
ChIP assay was conducted by using the ChIP assay kit (Cell Signaling Technology) following the manufacturer's protocol. In brief, cells at 80% confluence were fixed with formaldehyde (1% final concentration directly to the culture media) for 10 minutes. Cells were then centrifuged, followed by 
In-vivo studies in xenograft tumor models
All animal studies were conducted by following standard principles and procedures approved by the Institutional Animal Ethics Committee (IAEC) of CSIR-Central Drug Research Institute. Following our well established colon cancer xenograft models as described earlier [26] , 2x10 6 cells (HT-29, DLD1, and HCT-116 control or CXCR4 KD) in 100μl PBS were subcutaneously inoculated into the flanks of the left and right hind leg respectively of each 4-6 weeks old nude Crl: CD1-Foxn1 nu mice.
Throughout the study, the tumor was measured with an electronic digital caliper at a regular interval, and the tumor volume was calculated using standard formula V = Π / 6 × a2 × b, where 'a'
is the short and 'b' is the long tumor axis. At the end of the experiment, mice were sacrificed, and subcutaneous tumors were dissected for further studies.
Parts of harvested tumors were minced into small pieces with sterile forceps in the laminar hood.
These pieces of tumors are digested with collagenase, and the cells were passed through a cell strainer of pore size 70 micron to get single cells. Isolated single cells from tumor were cultured under puromycin selection for further experiments.
Analysis of GDC TCGA Breast Cancer (BRCA) dataset
Illumina HiSeq mRNA data of Breast Cancer Cell Lines (Heiser 2012) and patients with breast cancer, GDC TCGA Breast Cancer (BRCA), was downloaded from the TCGA portal for CXCR4
and DR5 genes using https://xena.ucsc.edu/ browser [27] . Log2 (fpkm-uq+1) values for CXCR4 and DR5 were converted into fold changes and compared to identify the association between CXCR4
and DR5 genes. Online software Heatmapper was used for the heatmap generation, and the clustering method used was Average Linkage, whereas the Euclidean distance measurement method was considered.
Immunofluorescent staining and confocal microscopy
Tumor samples resected from breast cancer patients (obtained from the surgical pathology at the SGPGI, Lucknow after having due Institutional ethical clearance) were fixed in 4% paraformaldehyde for 48 hours and embedded in paraffin wax. The staining of sections was performed as per the manufacturer's recommendations (Vector Laboratories). In brief, tissue sections were de-paraffinized and rehydrated in graded alcohol. Antigen retrieval was performed by immersing slides in 10 mM sodium citrate buffer (pH 6) and boiled in a high-power microwave oven for 25 minutes. Tissue sections were then washed with PBS followed by 25-minute incubation in bloxall to neutralize endogenous peroxide activity and subsequently incubated with primary monoclonal antibodies against CXCR4 (1:800) and DR5 (1:400) in 2% BSA overnight at 4°C. The next day, the appropriate fluorochrome-conjugated secondary antibody was added and incubated for one hour. The tissue sections were then mounted by using antifade (GIBCO). Stained sections were observed under a confocal microscope (Zeiss Meta 510 LSM; Carl Zeiss). It is necessary to mention that detecting DR5 in tissue sections is challenging due to poor availability of compatible DR5
antibodies. We tried multiple antibodies for DR5 staining in tumor tissue sections and the best one is represented in the figure.
Statistics
Most of the in vitro experiments are representative of at least three independent experiments.
Student's t-test and two-tailed distributions were used to calculate the statistical significance of in vitro and in vivo experiments. These analyses were done with GraphPad Prism. Results were considered statistically significant when p-values ≤ 0.05 between groups.
Results

CXCR4 but not CXCR7 regulates paclitaxel resistance in cancer
CXCL12 mediates its signals via CXCR4 and CXCR7 [11, 16, 28] , and these signaling axes have shown to be hyperactivated in cancer with poor clinical outcome [29, 30] . Here, we sought to determine the impact of these chemokine receptors (CXCR4 and CXCR7) on chemotherapy resistance. For our gain of function studies, we selected the MCF-7 cell as it showed very negligible surface expression of both CXCR4 and CXCR7. After confirming stable CXCR4 and CXCR7 overexpression in MCF-7 cells compared to vector control (Figure 1a ), we exposed cells with FDA approved anticancer drugs like Doxorubicin (250 nM), Paclitaxel (25 nM), Cisplatin (2.5 M), and 5-Fluorouracil (25M) and assessed cytotoxic effects of these drugs by SRB assay. As observed in 
CXCR4 inversely regulates expression and function of DR5
Reciprocal regulation of chemotherapy (paclitaxel) resistance with CXCR4 expression prompted us to understand further CXCR4 regulated priming of cell death mechanisms. To explore the molecular mechanism of CXCR4 mediated therapeutic resistance, we made use of an apoptosis antibody array (ARY009, R&D Systems). This array platform is unique and an unbiased approach to study the simultaneous expression of 35 apoptosis-related proteins spanning both intrinsic and extrinsic pathways. Surprisingly, in our array hybridized with an equal quantity of proteins from CXCR4
overexpressing and control MCF7 cells, we found very selective marked reduction of expression of pro-apoptotic protein DR5 in CXCR4 overexpressed cells as compared to control cells, whereas, changes in other apoptotic proteins were found to be minimal ( Figure. Altogether, our intricate experimental planning demonstrates that CXCR4 inversely alters the expression of DR5, and loss of its function results in TRAIL-mediated sensitization of cancer cells.
CXCR4 mediated DR5 downregulation is dependent on the recruitment of transcription factors p53 and YY1 to its promoter
To ascertain that the alteration of DR5 expression is at the transcriptional level also, mRNA expression was assessed by real-time PCR in control, and CXCR4 overexpressed/knockdown cells. however, to our surprise, we were unable to detect any CXCL12 in the medium (data not shown).
This unexpected result prompted us to carry out further experiments to determine the contribution of CXCL12-CXCR4 signaling axis in pro-tumorigenic functions of CXCR4 observed earlier. To block CXCR4 mediated signals, we used FDA approved CXCR4 antagonist AMD3100 [35, 36] . We treated our control and CXCR4 overexpressed MCF-7 cells either with AMD3100 or CXCL12 and sought to observe the change in suppressed DR5 expression. Unexpectedly, compared to control, we did not observe any rescue (in case of AMD3100 treatment) or further suppression (CXCL12 treatment) of DR5 expression following respective treatments (Figure 4a ). To further validate our previous observations, we selected the HT-29 cell, which has been shown to highly express CXCR4 on its cell surface. In order to mimic the phenotype of our CXCR4 knockdown experiments, HT29 cells were treated with AMD3100 and paclitaxel alone and in combination to assess any synergistic cytotoxic effect of paclitaxel under CXCL12-CXCR4 inhibited condition. However, to our great surprise, we did not find any significant synergistic cytotoxic effect in combination treatment (AMD3100 plus paclitaxel) compared to individual treatments (Figure 4a ). Two entirely unexpected observations forced us to test the efficacy of AMD3100 and CXCL12 in our system. As ERK phosphorylation is a classical downstream signature of the CXCR4-CXCL12 axis, we examined the effect of CXCL12 and AMD3100 on the regulation of phosphorylation of ERK in HT29 cells. As expected, CXCL12 mediated ERK phosphorylation was found to be markedly inhibited by AMD3100 treatment, strongly advocating the fact that both CXCL12 and AMD3100 are fine and functional in our system and confirmed the accuracy of our previous unexpected observations 
Loss of CXCR4 protein results in compromised colon tumor growth in vivo
A series of earlier in vitro experiments across diverse human cancer types suggested CXCR4
protein, but not its ligand-mediated signals are critical for CXCR4 mediated paclitaxel resistance and CXCR4 protein inversely regulates expression of pro-apoptotic protein DR5. To validate our atypical in vitro observation into an in vivo system, we picked three different colon cancer cell lines (Figure 5g, 5h) . Together, our xenograft experiments in the animal also suggest that CXCR4 protein, but not its ligand-mediated signals are essential in modulating in vivo tumor growth.
Expression of CXCR4 and DR5 are inversely correlated in human breast cancer samples
To understand the pathophysiological significance of our finding in context of human cancer, we exploited TCGA database to find out clinical correlation between CXCR4 and DR5, especially could be a critical indicator for predicting therapy response as well as the aggressiveness of particular cancer.
Discussion
The lineage of CXCR4 with its pro-tumorigenic functions in solid tumors is unequivocal. Earlier publications suggest that the CXCR4-CXCL12 axis is not only pivotal for modulating cancer metastasis but also responsible for executing its other tumor-promoting functions [11, 37, 38] .
Despite vast preclinical evidence, CXCR4 inhibitor 'Plerixafor' or AMD3100 got FDA approval as a stem cell mobilizer [39] , not as a cancer drug or even as a metastasis inhibitor. The discrepancy of preclinical observations and limited clinical success of CXCR4 antagonists as cancer therapy strongly advocates the involvement of some other aspects of CXCR4 biology beyond its classical CXCR4-CXCL12 signaling axis. Our data for the first time, suggests that intracellular presence of CXCR4 protein, but neither its surface expression nor CXCL12-CXCR4 mediated signals are essential in modulating therapy (paclitaxel) resistance in cancer. Our results also justify to some extent why the CXCR4 inhibitor phenotype does not match with the CXCR4 null/knock-out phenotype under different preclinical settings.
Initially, we considered both CXCR4 and CXCR7 to study the impact of these two chemokine receptors to understand therapy resistance in cancer as they share common ligand CXCL12, and are shown to be overexpressed in different solid tumors [11, 14] . However, we observed selective involvement of CXCR4 in significantly modulating paclitaxel resistance in breast and colon cancers, which is actually in corollary with vast literature documenting the pro-tumorigenic role of CXCR4.
Drug resistance is one of the identifying features of Cancer stem cells (CSCs) [40] [41] [42] [43] and CXCR4;
being a bona fide CSC marker for prostate and pancreatic cancers [44, 45] , evidently support its presence to promote therapy resistance. Also, studies in AML and NSCLC showed the presence of CXCR4 has a positive correlation with therapy resistance though they consider ligand-mediated signals as a responsible reason for the same [46, 47] . Our unbiased mechanistic hunt discovered that CXCR4 mediates therapy resistance via selectively regulating the pro-apoptotic candidate protein DR5 by differentially modulating YY1 recruitment at the promoter site of the DR5 gene. Differential YY1 recruitment in the promoter region for activation and repression of target genes is documented by earlier elegant studies [48, 49] . Further, CXCR4-YY1 reciprocal regulation has been well documented as a pro-tumorigenic function of CXCR4 in AML therapy resistance and osteosarcoma angiogenesis [46, 50] . CXCR4 is rarely found to be localized in the nucleus which has been shown to be linked with poor prognosis and enhanced metastasis [51, 52] . Nuclear localization of CXCR4 may be associated with transcriptional upregulation of YY1 and its differential recruitment to the promoter region of DR5 gene. Though CXCR4 mediated DR5 transcriptional regulation is our novel finding, it has been reported in the studies that high CXCR4 expression in the cancer cells is correlated with poor prognosis and resistance against the various DNA damaging chemotherapeutic agents whose mechanism of action involve the regulation of Death receptors [53, 54] .
Utilizing three different xenograft models of colon cancer cells that are either expressing surface CXCR4 (HT-29) or are null for the CXCR4 surface expression (DLD-1, HCT-116), we provided strong evidence that knockdown of CXCR4 results in reduced tumor growth irrespective of their surface expression status ( Figure 5 and Supplementary Figure 1) . In support of our in vivo observations, several previous studies have demonstrated that CXCR4 knockdown cells produce smaller tumors as compared to their control counterparts [38, 55, 56] . Interestingly, at least one study indicated that the cytoplasmic expression of CXCR4 is correlated with tumor burden and the metastatic load of certain cancers [57] . Further, some reports have suggested that the in vivo environment gives cues to the cancer cells to transport their intracellular CXCR4 on the surface [37, 58] , so to test the same, we isolated single cells from harvested in vivo xenograft tumors and examined the CXCR4 surface expression. However, no change was found in the surface expression of CXCR4 either in control or the knockdown cells suggesting the fact that though they gave rise to smaller tumors compared to control, there is no contribution of CXCR4-CXCL12 signaling axis in delivering this phenotype. Inverse correlation of CXCR4 and DR5 expression was observed in our human breast cancer samples, which was primarily allied with TCGA data obtained from a broad panel of breast cancer cell lines as well as data from human TCGA Breast Cancer (BRCA) cohort suggesting the clinical significance of our finding.
Overall, the study indicates that high expression of CXCR4 protein but not CXCR4 signaling 
Conflicts of Interest Statement
The authors declare no conflicts of interest. 
Author Contributions
